COMy 2023 | Updates on the use of melflufen in R/R multiple myeloma

Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, shares some insights into the use of the first-in-class peptide-drug conjugate melflufen for treating patients with relapsed/refractory multiple myeloma (R/R MM). Dr Cerchione explains that many patients with MM relapse after multiple prior lines of antibody-based or cellular therapy. However, recent data from the HORIZON (NCT02963493) and OCEAN (NCT03151811) clinical trials have demonstrated the efficacy of melflufen in this patient group. Dr Cerchione further notes that melflufen is currently best used as a monotherapy but may be beneficial in combination therapies with further research. This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.